Immune Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Immune Pharmaceuticals generated cash of -$11,559,000, which is more than the previous year. Cash used in financing activities reached the amount of $18,033,000 last year. Net change in cash is therefore $6,505,000.
Cash Flow
| 2010 | -10.4M | 63K | 7.63M |
|---|---|---|---|
| 2011 | -14.00M | 97K | 17.84M |
| 2012 | -5.33M | -867K | -13K |
| 2013 | -3.86M | -1.13M | 4.95M |
| 2014 | -13.86M | 117K | 20.46M |
| 2015 | -13.90M | -177K | 11.85M |
| 2016 | -12.30M | -50K | 8.08M |
| 2017 | -11.55M | 31K | 18.03M |
IMNP Cash Flow Statement (2010 – 2017)
| 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 271K | 4.54M | 6.76M | 49K | 95K | 6.37M | 2.43M | 5.14M |
Operating activities | ||||||||
Net income | -17.88M | -32.66M | -17.15M | -23.55M | -5.76M | -2.57M | -15.65M | -15.53M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 3.30M | 999K | 649K | 283K | 308K | 545K | 1.02M | 170K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 3.30M | 692K | 930K | 935K |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 3.30M | 692K | 930K | 935K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 360K | -16K | 852K |
Accounts payable | -30K | 1.25M | -30K | -439K | 391K | 225K | -122K | -602K |
Cash generated by operating activities | -11.55M | -12.30M | -13.90M | -13.86M | -3.86M | -5.33M | -14.00M | -10.4M |
Investing activities | ||||||||
Purchases Of Investments | 238K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -28K | -21K | -167K | -23K | 0 | 0 | -26K | -2K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 31K | -50K | -177K | 117K | -1.13M | -867K | 97K | 63K |
Financing activities | ||||||||
Common Stock Issued | 0 | 2.44M | 0 | 11.02M | 4.36M | 300K | 10.87M | 8.08M |
Payments for dividends | 0 | 0 | 0 | 0 | -932K | 0 | 0 | 0 |
Repurchases of common stock | -6.77M | -271K | -4.54M | -6.76M | -49K | -172K | -6.37M | 0 |
Repayments of term debt | 0 | -505K | 0 | -1.48M | -7K | -4.31M | -1.35M | 4K |
Cash used in financing activities | 18.03M | 8.08M | 11.85M | 20.46M | 4.95M | -13K | 17.84M | 7.63M |
Net Change In Cash | 6.50M | -4.27M | -2.22M | 6.71M | -46K | -6.20M | 3.94M | -2.70M |
Cash at end of period | 6.77M | 271K | 4.54M | 6.76M | 49K | 172K | 6.37M | 2.43M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |